Product Center
The Ab&B Bio Promotion Business Conference and 10th Anniversary Celebration were successfully held
- Categories:Company news
- Author:
- Origin:
- Time of issue:2026-04-25
- Views:
(Summary description)Innovate with wisdom, embark on a new journey together. On April 23-24, 2026, Ab&B Bio-Tech Co., Ltd. JS (hereinafter referred to as "Ab&B Bio") successfully held the "Innovate with wisdom, and move forward together towards a brilliant future." Promotion Conference and the company's 10th anniversary celebration. Partners, industry experts, and company management from all over the country gathered together to visit the latest developments in the three major industrialization bases, gather consensus, and embark on the third five-year journey of struggle together!
The Ab&B Bio Promotion Business Conference and 10th Anniversary Celebration were successfully held
(Summary description)Innovate with wisdom, embark on a new journey together. On April 23-24, 2026, Ab&B Bio-Tech Co., Ltd. JS (hereinafter referred to as "Ab&B Bio") successfully held the "Innovate with wisdom, and move forward together towards a brilliant future." Promotion Conference and the company's 10th anniversary celebration. Partners, industry experts, and company management from all over the country gathered together to visit the latest developments in the three major industrialization bases, gather consensus, and embark on the third five-year journey of struggle together!
- Categories:Company news
- Author:
- Origin:
- Time of issue:2026-04-25 11:29
- Views:
Innovate with wisdom, embark on a new journey together. On April 23-24, 2026, Ab&B Bio-Tech Co., Ltd. JS (hereinafter referred to as "Ab&B Bio") successfully held the "Innovate with wisdom, and move forward together towards a brilliant future." Promotion Conference and the company's 10th anniversary celebration. Partners, industry experts, and company management from all over the country gathered together to visit the latest developments in the three major industrialization bases, gather consensus, and embark on the third five-year journey of struggle together!
On the eve of the conference, the company organized all representatives of promoters to visit the company's three major industrialization bases. At present, all three production parks have been fully formed, laying a solid production capacity foundation for the commercialization of multi variety pipelines in the future. Each park is advancing the workshop decoration and equipment installation work in a scientific and orderly manner based on the company's pipeline research and development progress. All construction production lines have achieved digital system control, covering quality assurance throughout the entire lifecycle.

In the workshops of freeze-dried human rabies vaccine (human diploid cells) and recombinant herpes zoster vaccine, cutting-edge equipment application and scientific flow line design allowed representatives to intuitively feel the company's solid foundation in industrialization. Many customers couldn't help but exclaim, "Seeing these hard power, we are full of confidence in future cooperation!”
In the workshops of freeze-dried human rabies vaccine (human diploid cells) and recombinant herpes zoster vaccine, cutting-edge equipment application and scientific flow line design allowed representatives to intuitively feel the company's solid foundation in industrialization. Many customers couldn't help but exclaim, "Seeing these hard power, we are full of confidence in future cooperation
Core goal: To become one of the top tier enterprises in Chinese human vaccines by the end of the third five years
Four major strategies: innovation driven, quality leadership, management efficiency improvement, and overseas expansion
Product Matrix: Build a vaccine product matrix driven by "prevention+tumor treatment" to accelerate breakthroughs in key technologies
Operation System: Build a three in one Ab&B Bio characteristic operation system of "AI intelligent research and development+intelligent manufacturing+precision marketing"
Operation System: Build a three in one Ab&B Bio characteristic operation system of "AI intelligent research and development+intelligent manufacturing+precision marketing"

The conference has specially invited experts from IQVIA to provide a themed training on "Breaking through Symbiosis: AI Driven Pharmaceutical Innovation and Commercialization Implementation". The expert system elaborates on the development process, core principles, application scenarios of commonly used tools, and real cases in various aspects of enterprise operation of AI. The training content provides solid theoretical support and practical path guidance for the company to build a three in one operation system of "AI intelligent research and development+intelligent manufacturing+precision marketing". The participating promoters all said, "It turns out that AI is so close to vaccine marketing, and the future really has arrived.”

Standing at the new starting point of the third five-year plan, Ab&B Bio will take "innovation driven" as the spear, "quality leadership" as the shield, "management efficiency improvement" as the foundation, and "overseas expansion" as the wing, working together with all promotional partners to continue striving towards the beautiful vision of enabling China to use global innovative vaccines and the world to use high-quality Chinese vaccines, and contributing more solid "vaccine power" to a healthy China!

Relevant information
-
How to choose a reliable influenza vaccine during the flu season? An evidence-based guide for subunit vaccines for all age groups
Influenza (commonly referred to as the flu) is an acute respiratory infectious disease caused by the influenza virus. Unlike the common cold, influenza is highly contagious and is characterized primarily by systemic symptoms. Elderly individuals, children under the age of 5, patients with chronic diseases, pregnant women, and individuals with compromised immune systems are all considered high-risk populations for severe influenza [1]. A study based on national influenza surveillance and cause-of-death surveillance data revealed that, on average, there are 88,000 excess deaths related to influenza-associated respiratory diseases annually across China [2]. The total economic burden on outpatient patients with influenza ranges from RMB 801 to RMB 1,320, while the total economic burden on hospitalized influenza patients ranges from RMB 9,832 to RMB 23,833 [1]. In the face of the significant challenge posed by influenza, influenza vaccination is currently recognized worldwide as the most cost-effective and effective means of preventing influenza [1]. - The leap in influenza vaccine technology: from split-virus vaccines to whole-population subunit vaccines – what are the key advancements in the third-generation vaccines? 08-19
- Exclusive Release | The influenza subunit vaccine "HRK-X® 3" makes its nationwide debut, ushering in a new chapter of scientific protection for all populations! 08-15
- High-dose influenza vaccines now available across the entire population – marking a new phase in influenza prevention and control with subunit vaccines 08-15
- Deepening Strategic Synergy to Jointly Strengthen Public Health Defense: Chongqing Center for Disease Control and Prevention (Chongqing Institute of Preventive Medicine) visited Ab&B Bio for a visit and exchange session. 08-06
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us